In an effort to battle growing criticism over rising drug prices, Eli Lilly and Co plan to sell a half-price version of its insulin product, Humalog, rebranded as Insulin Lispro. It will be sold only in the U.S. at $137.35 per vial.
Where does this stem from?
Last month, two U.S. Senators launched an investigation over rising insulin prices, and the companies involved fought back.
The cost of treating type 1 diabetes nearly doubled over a five-year period. In fact, Lilly’s Humalog rose from $35 to $234 (585%) between 2001 and 2015.
Image Source: Axios